Background: Local treatment improves the outcomes for oligometastatic disease (OMD, i.e. an intermediate state between locoregional and widespread disseminated disease). However, consensus about the definition, diagnosis and treatment of oligometastatic oesophagogastric cancer is lacking. The aim of this study was to develop a multidisciplinary European consensus statement on the definition, diagnosis and treatment of oligometastatic oesophagogastric cancer. Methods: In total, 65 specialists in the multidisciplinary treatment for oesophagogastric cancer from 49 expert centres across 16 European countries were requested to participate in this Delphi study. The consensus finding process consisted of a starting meeting, 2 online Delphi questionnaire rounds and an online consensus meeting. Input for Delphi questionnaires consisted of (1) a systematic review on definitions of oligometastatic oesophagogastric cancer and (2) a discussion of real-life clinical cases by multidisciplinary teams. Experts were asked to score each statement on a 5-point Likert scale. The agreement was scored to be either absent/poor (<50%), fair (50%-75%) or consensus (≥75%). Results: A total of 48 experts participated in the starting meeting, both Delphi rounds, and the consensus meeting (overall response rate: 71%). OMD was considered in patients with metastatic oesophagogastric cancer limited to 1 organ with ≤3 metastases or 1 extra-regional lymph node station (consensus). In addition, OMD was considered in patients without progression at restaging after systemic therapy (consensus). For patients with synchronous or metachronous OMD with a disease-free interval ≤2 years, systemic therapy followed by restaging to consider local treatment was considered as treatment (consensus). For metachronous OMD with a disease-free interval >2 years, either upfront local treatment or systemic treatment followed by restaging was considered as treatment (fair agreement). Conclusion: The OMEC project has resulted in a multidisciplinary European consensus statement for the definition, diagnosis and treatment of oligometastatic oesophagogastric adenocarcinoma and squamous cell cancer. This can be used to standardise inclusion criteria for future clinical trials.
Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe / Kroese, Tiuri E; van Laarhoven, Hanneke W M; Schoppman, Sebastian F; Deseyne, Pieter R A J; van Cutsem, Eric; Haustermans, Karin; Nafteux, Philippe; Thomas, Melissa; Obermannova, Radka; Mortensen, Hanna R; Nordsmark, Marianne; Pfeiffer, Per; Elme, Anneli; Adenis, Antoine; Piessen, Guillaume; Bruns, Christiane J; Lordick, Florian; Gockel, Ines; Moehler, Markus; Gani, Cihan; Liakakos, Theodore; Reynolds, John; Morganti, Alessio G; Rosati, Riccardo; Castoro, Carlo; Cellini, Francesco; D'Ugo, Domenico; Puccetti, Francesco; Roviello, Franco; Bencivenga, Maria; de Manzoni, Giovanni; van Berge Henegouwen, Mark I; Hulshof, Maarten C C M; van Dieren, Jolanda; Vollebergh, Marieke; van Sandick, Johanna W; Jeene, Paul; Muijs, Christel T; Slingerland, Marije; Voncken, Francine E M; Hartgrink, Henk; Creemers, Geert-Jan; van der Sangen, Maurice J C; Nieuwenhuijzen, Grard; Berbee, Maaike; Verheij, Marcel; Wijnhoven, Bas; Beerepoot, Laurens V; Mohammad, Nadia H; Mook, Stella; Ruurda, Jelle P; Kolodziejczyk, Piotr; Polkowski, Wojciech P; Wyrwicz, Lucjan; Alsina, Maria; Pera, Manuel; Kanonnikoff, Tania F; Cervantes, Andrés; Nilsson, Magnus; Monig, Stefan; Wagner, Anna D; Guckenberger, Matthias; Griffiths, Ewen A; Smyth, Elizabeth; Hanna, George B; Markar, Sheraz; Chaudry, M Asif; Hawkins, Maria A; Cheong, Edward; van Hillegersberg, Richard; van Rossum, Peter S N. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 1879-0852. - 185:(2023), pp. 28-39. [10.1016/j.ejca.2023.02.015]
Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe
Rosati, Riccardo;Puccetti, FrancescoMembro del Collaboration Group
;
2023-01-01
Abstract
Background: Local treatment improves the outcomes for oligometastatic disease (OMD, i.e. an intermediate state between locoregional and widespread disseminated disease). However, consensus about the definition, diagnosis and treatment of oligometastatic oesophagogastric cancer is lacking. The aim of this study was to develop a multidisciplinary European consensus statement on the definition, diagnosis and treatment of oligometastatic oesophagogastric cancer. Methods: In total, 65 specialists in the multidisciplinary treatment for oesophagogastric cancer from 49 expert centres across 16 European countries were requested to participate in this Delphi study. The consensus finding process consisted of a starting meeting, 2 online Delphi questionnaire rounds and an online consensus meeting. Input for Delphi questionnaires consisted of (1) a systematic review on definitions of oligometastatic oesophagogastric cancer and (2) a discussion of real-life clinical cases by multidisciplinary teams. Experts were asked to score each statement on a 5-point Likert scale. The agreement was scored to be either absent/poor (<50%), fair (50%-75%) or consensus (≥75%). Results: A total of 48 experts participated in the starting meeting, both Delphi rounds, and the consensus meeting (overall response rate: 71%). OMD was considered in patients with metastatic oesophagogastric cancer limited to 1 organ with ≤3 metastases or 1 extra-regional lymph node station (consensus). In addition, OMD was considered in patients without progression at restaging after systemic therapy (consensus). For patients with synchronous or metachronous OMD with a disease-free interval ≤2 years, systemic therapy followed by restaging to consider local treatment was considered as treatment (consensus). For metachronous OMD with a disease-free interval >2 years, either upfront local treatment or systemic treatment followed by restaging was considered as treatment (fair agreement). Conclusion: The OMEC project has resulted in a multidisciplinary European consensus statement for the definition, diagnosis and treatment of oligometastatic oesophagogastric adenocarcinoma and squamous cell cancer. This can be used to standardise inclusion criteria for future clinical trials.| File | Dimensione | Formato | |
|---|---|---|---|
|
1.pdf
accesso aperto
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Creative commons
Dimensione
1.58 MB
Formato
Adobe PDF
|
1.58 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
